Human experimentation with Neisseria gonorrhoeae: Progress and goals

Journal of Infectious Diseases

Volumn 179, Issue SUPPL. 2, 1999, Pages

  Cohen, Myron S ^a   Cannon, Janne G ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BINDING PROTEIN; LACTOFERRIN; PILIN; TRANSFERRIN;

CONFERENCE PAPER; GENE INACTIVATION; GONORRHEA; HUMAN; IMMUNE RESPONSE; MALE; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; URETHRITIS;

EID: 0033372331     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513847     Document Type: Conference Paper

References (30)

1. 1. World Health Organization. An overview of selected curable sexually transmitted diseases. Geneva: WHO Global Programme on AIDS, 1995.
2. 2. Royce RA, Seña A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997;336:1072-8.
3. 3. Lucas CT, Chandler F, Martin JE, Schmale JD. Transfer of gonococcal urethritis from man to chimpanzee: an animal model for gonorrhea. JAMA 1971;216:1612-4.
4. 4. Adimora AA, Sparling PF, Cohen MS. Vaccines for classic sexually transmitted diseases. Infect Dis Clin North Am 1994;8:859-87.
5. 5. Kellogg DS Jr, Peacock WL Jr, Deacon WE, Brown L, Pirkle CI. Neisseria gonorrhoeae. I. Virulence genetically linked to clonal variation. J Bacteriol 1963;85:1274-9.
6. 6. Swanson J, Robbins K, Barrera O, et al. Gonococcal pilin variants in experimental gonorrhea. J Exp Med 1987;165:1344-57.
7. 7. Jerse AE, Cohen MS, Drown PM, et al. Multiple gonococcal opacity proteins are expressed during experimental urethral infection in the male. J Exp Med 1994;179:911-20.
8. 8. Seifert HS, Wright CJ, Jerse AE, Cohen MS, Cannon JG. Multiple gonococcal pilin antigenic variants are produced during experimental human infections. J Clin Invest 1994;93:2744-9.
9. 9. Schneider H, Griffiss JM, Boslego JW, Hitchcock PJ, Zahos KM, Apicella MA. Expression of paragloboside-like lipooligosaccharides may be a necessary component of gonococcal pathogenesis in men. J Exp Med 1991;174:1601-5.
10. 10. Ramsey KH, Schneider H, Cross AS, et al. Inflammatory cytokines produced in response to experimental human gonorrhea. J Infect Dis 1995; 172:186-91.
11. 11. Warren RL, Van De Verg LL, Schmidt KA, et al. Differential antibody and cytokine responses in male volunteers experimentally infected with Neisseria gonorrhoeae MS1 1mkC. In: Zollinger WD, Frasch CE, Deal CD, eds. Abstracts of the Tenth International Pathogenic Neisseria Conference (Baltimore), 1996:56.
12. 12. Hill J. Experimental infection with Neisseria gonorrhoeae. I. Human inoculations. Am J Syphilis Gonorrhea Vener Dis 1943;27:733-71.
13. 13. Brinton CC Jr, Wood SW, Brown A, et al. The development of a neisserial pilus vaccine for gonorrhea and meningococcal meningitis. In: Weinstein L, Fields BN, eds. Meningococcal and gonococcal pilus vaccines. New York: Thieme-Stratton, 1982:140-59.
14. 14. Swanson J, Barrera O, Sola J, Boslego J. Expression of outer membrane protein II by gonococci in experimental gonorrhea. J Exp Med 1988; 168:2121-9.
15. 15. Cohen MS, Cannon JG, Jerse AE, Charniga LM, Isbey SF, Whicker LG. Human experimentation with Neisseria gonorrhoeae: rationale, methods, and implications for the biology of infection and vaccine development. J Infect Dis 1994;169:532-7.
16. 16. Schneider H, Cross AS, Kuschner RA, et al. Experimental human gonococcal urethritis: 250 Neisseria gonorrhoeae MS1 1mkC are ineffective. J Infect Dis 1995;172:180-5.
17. 17. Isbey SF, Alcorn TM, Davis RH, Haizlip J, Leone PA, Cohen MS. Characterization of Neisseria gonorrhoeae in semen during urethral infection in men. Genitourin Med 1997;73:378-82.
18. 18. Schneider H, Lindstrom JA, Schmidt KA, Boslego JW, Warren R, Van De Verg L. Does an experimental gonococcal infection protect human volunteers from subsequent reinfection? In: Zollinger WD, Frasch CE, Deal CD, eds. Abstracts of the Tenth International Pathogenic Neisseria Conference (Baltimore), 1996:13.
19. 19. Dyer DW, Gray E, Behrens BX, et al. The neisserial genome: importance and where do we stand? In: Zollinger WD, Frasch CE, Deal CD, eds. Abstracts of the Tenth International Pathogenic Neisseria Conference (Baltimore), 1996.
20. 20. Rudel T, van Putten JPM, Gibbs CP, Haas R, Meyer TF. Interaction of two variable proteins (PilE and PilC) required for pilus-mediated adherence of Neisseria gonorrhoeae to human epithelial cells. Mol Microbiol 1992;6:3439-50.
21. 21. Weel JF, Hopman CT, van Putten JP. In situ expression and localization of Neisseria gonorrhoeae opacity proteins in infected epithelial cells: apparent role of Opa proteins in cellular invasion. J Exp Med 1991; 173:1395-405.
22. 22. Van Putten JP. Phase variation of lipopolysaccharide directs interconversion of invasive and immuno-resistant phenotypes of Neisseria gonorrhoeae. Embo J 1993;12;4043-51.
23. 23. Schneider HK, Schmidt A, Skillman DR, et al. Sialylation lessens the infectivity of Neisseria gonorrhoeae MS1 1MkC. J Infect Dis 1996;173: 1422-7.
24. 24. Johnston DM, Isbey SF, Snodgrass TL, Apicella M, Zhou D, Cannon JG. A strategy for constructing mutant strains of Neisseria gonorrhoeae containing no new antibiotic resistance markers using a two gene cassette with selectable and counterselectable markers, and its use in constructing a pgm mutant for use in human challenge trials. In: Zollinger WD, Frasch CE, Deal CD, eds. Abstracts of the Tenth International Pathogenic Neisseria Conference (Baltimore), 1996:37.
25. 25. Cornelissen CN, Anderson JE, Kashkari M, et al. Function and virulence studies of the gonococcal transferrin receptor. In: Zollinger WD, Frasch CE, Deal CD, eds. Abstracts of the Tenth International Pathogenic Neisseria Conference (Baltimore), 1996:552.
26. 26. Rice PA, Gulati S, McQuillen DP, Ram S. Is there protective immunity to gonococcal disease? In: Zollinger WD, Frasch CE, Deal CD, eds. Abstracts of the Tenth International Pathogenic Neisseria Conference (Baltimore), 1996:3.
27. 27. Boslego JW, Tramont EC, Chung RC, et al. Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine 1991;9:154-62.
28. 28. Hook EW 3d, Olsen DA, Buchanan TM. Analysis of the antigen specificity of the human serum immunoglobulin G immune response to complicated gonococcal infection. Infect Immun 1984;43:706-9.
29. 29. Plummer FA, Simonsen H, Chubb H, et al. Epidemiologic evidence for the development of serovar-specific immunity after gonococcal infection. J Clin Invest 1989;83:1472-6.
30. 30. Rice PA, Vayo HE, Tam MR, Blake MS. Immunoglobulin G antibodies directed against protein III block killing of serum resistant Neisseria gonorrhoeae by immune serum. J Exp Med 1986;164:1735-48.